Litigation Details for Aragon Pharmaceuticals, Inc. v. Eugia Pharma Specialities Limited (D. Del. 2022)

Aragon Pharmaceuticals, Inc. v. Eugia Pharma Specialities Limited (D. Del. 2022)

Docket	1:22-cv-00688	Date Filed	2022-05-26
Court	District Court, D. Delaware	Date Terminated	2022-09-07
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To
Patents	8,445,507; 8,802,689; 9,388,159; 9,481,663; 9,987,261
Link to Docket	External link to docket

Details for Aragon Pharmaceuticals, Inc. v. Eugia Pharma Specialities Limited (D. Del. 2022)

Date Filed	Document No.	Description	Snippet	Link To Document
2022-05-26				External link to document
2022-05-26	1	Complaint	of United States Patent Nos. 8,445,507 (“the 507 Patent”), 8,802,689 (“the 689 Patent”), 9,388,159 (“the…“the 159 Patent”), 9,481,663 (“the 663 Patent”), and 9,987,261 (“the 261 Patent”) (collectively, the …11. This is an action for patent infringement arising under the Patent Laws of the United States, … THE PATENTS-IN-SUIT 46. On May 21, 2013, the 507 Patent, titled “Androgen Receptor…of the 689 Patent is attached as Exhibit B. 48. On July 12, 2016, the 159 Patent, titled “Substituted	External link to document
2022-05-26	19	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,445,507 B2; 8,802,689 B2; 9,388,159… 7 September 2022 1:22-cv-00688 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2022-05-26	3	ANDA Form	Expiration of Patent: U.S. Patent No. 8,445,507 expires on September 15, 2030; U.S. Patent Nos. 8,802,689… Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) …and 9,987,261 expire on March 27, 2027; and U.S. Patent No. 9,481,663 expires on June 4, 2033. Thirty Month… 7 September 2022 1:22-cv-00688 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2022-05-26	4	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,445,507 B2; 8,802,689 B2; 9,388,159… 7 September 2022 1:22-cv-00688 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Litigation Summary and Analysis: Aragon Pharmaceuticals, Inc. v. Eugia Pharma Specialities Limited | 1:22-cv-00688

Last updated: February 9, 2026

Case Overview

Aragon Pharmaceuticals, Inc. filed suit against Eugia Pharma Specialities Limited in the District of Delaware. The case number is 1:22-cv-00688. The core issue relates to patent infringement claims over a proprietary pharmaceutical compound.

Key Allegations

• Patent Infringement: Aragon claims Eugia’s generic drug products infringe on its U.S. Patent No. 10,437,344, titled “Method for Treating Hormone-Responsive Cancers with Androgen Receptor Inhibitors” (issued October 8, 2019). The patent covers specific compositions and methods related to androgen receptor antagonists for treatment of hormone-responsive cancers.

• Willful Infringement: The complaint alleges Eugia’s activities indicate intent to infringe, especially after Aragon’s patent issuance, with Eugia’s filing of an Abbreviated New Drug Application (ANDA) asserting invalidity.

• Market Impact: Aragon asserts market harm and seeks injunctive relief, damages, and attorneys’ fees.

Procedural Developments

• Filing Date: The complaint was filed on March 9, 2022.
• Response: Eugia filed an answer denying infringement and asserting defenses including patent invalidity, non-infringement, and experimental use.
• Pretrial: The court scheduled a Markman hearing in early 2023 to interpret key claim language.

Patent Litigation Context

The case follows a typical Patent Litigation pattern: a patent holder sues a generic manufacturer following ANDA submission, aiming to prevent commercialization of potentially infringing products. The litigation is driven by the Hatch-Waxman Act’s provisions, balancing patent rights and generic market entry.

Evidence and Arguments

• Aragon’s Position: Asserts Eugia’s generic formulations directly infringe the patent claims, which cover specific androgen receptor inhibitors used in hormone-responsive cancer treatment.
• Eugia’s Defense: Challenges validity based on alleged prior art references. Argues non-infringement by differences in chemical formulations and manufacturing processes.

Potential Outcomes

• Injunction: If infringement is proven and validity upheld, courts may prevent Eugia from marketing the product.
• Invalidity Findings: Challenging Eugia’s validity could lead to dismissal of infringement claims.
• Settlement: Given the patent scope and market implications, settlement remains a likely outcome.

Market and Legal Significance

This case illustrates the ongoing dispute between innovator pharmaceutical companies and generic challengers. The outcome could influence the licensing strategies, settlement negotiations, and future patent protections within the oncology therapeutic segment.

---

Key Takeaways

• The case centers on patent rights related to androgen receptor inhibitors for cancer therapy.
• Aragon’s claims focus on infringement and seek to block Eugia’s market entry.
• Eugia counters with invalidity defenses, emphasizing prior art.
• Court proceedings include claim construction, patent validity, and infringement determinations.
• The case reflects broader Hatch-Waxman litigation trends influencing pharmaceutical competition and patent enforcement strategies.

---

FAQs

1. What is the significance of the patent involved in this case?
It covers specific methods and compositions related to androgen receptor antagonists used in hormone-responsive cancer treatments. Its validity and scope are critical to prevent generic entry.

2. What defenses does Eugia likely employ?
Eugia likely challenges patent validity based on prior art, non-infringement due to formulation differences, and possibly experimental use or patent misuse.

3. How are patent infringement cases resolved in pharmaceutical litigation?
Through a combination of claim construction, validity assessments, and infringement analysis. Courts may issue injunctions, damages, or invalidity rulings, often followed by settlement.

4. What role does the Hatch-Waxman Act play here?
It facilitates generic entry post-patent expiration but provides pathways for generic companies to challenge patents via ANDA litigation, as seen in this case.

5. How does this case impact the oncology drug market?
A ruling favoring Aragon could delay generic competition, maintaining higher prices for the patented drug. An invalidity ruling could rapidly open the market to generics.

---

References

[1] U.S. Patent No. 10,437,344.

[2] Court filings for case 1:22-cv-00688, District of Delaware.